We have just released the latest update to the Open Targets Platform — 24.03.
Key highlights for this release:
This release integrates 17,317,290 evidence strings to build 7,802,260 target-disease associations between 25,817 diseases and 63,226 targets from the following 23 public resources:
- 2,999,652 genetic evidence from European Variation Archive (EVA)
- 781,437 genetic evidence from Open Targets Genetics
- 3,118 genetic evidence from Gene2Phenotype
- 31,921 genetic evidence from the Genomics England PanelApp
- 2,416 genetic evidence from ClinGen
- 6,473 genetic evidence from Orphanet
- 27,381 genetic evidence from Gene burden
- 21,726 genetic evidence from CRISPRBrain
- 4,168 genetic evidence from UniProt Literature
- 16,927 somatic evidence from European Variation Archive (EVA)
- 4,359 somatic evidence from intOGen
- 82,754 somatic evidence from the Cancer Gene Census
- 26,217 somatic evidence from Uniprot
- 624,491 drug evidence from ChEMBL
- 230,182 expression evidence from Expression Atlas
- 10,160 affected pathway evidence from Reactome
- 72,441 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,300 somatic evidence from the Cancer Genome Interpreter
- 517 CRISPR-Cas9 (Cancer Cell Lines) evidence from Pacini et al. (2024)
- 1,082,451 mouse model evidence from IMPC
- 11,286,432 scientific literature evidence from co-occurrence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 17,111 drugs.
For more details, read the 24.03 blog post.